Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12 – 16, 2025. The management team will also participate in one-on-one investor meetings.
加利福尼亞州布里斯班，2025年1月7日（全球新聞社）-- Vera Therapeutics, Inc.（納斯達克：VERA）是一家處於臨牀後期的生物技術公司，專注於開發和商業化針對嚴重免疫疾病患者的變革性治療。今天，公司管理團隊宣佈將參加第43屆年度摩根大通醫療健康大會，會議將在2025年1月12日至16日在加州舊金山舉行。管理團隊還將參加一對一的投資者會議。
Presentation Details:
Date: Monday, January 13, 2025
Time: 4:30 PM PST
Webcast:
展示詳情：
日期：2025年1月13日，星期一
時間：下午4:30 太平洋標準時間
網絡直播：
A replay of the event will be available for 90 days and can be accessed by visiting the "Investor Calendar" section of the Vera Therapeutics website.
活動回放將在90天內提供，您可以通過訪問Vera Therapeutics網站的「投資者日歷」部分進行訪問。
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger's disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit .
關於Vera
Vera Therapeutics是一家處於臨牀後期的生物技術公司，專注於開發嚴重免疫疾病的治療方案。Vera的使命是推動針對免疫疾病根源的治療，以改變患者的護理標準。Vera的主要產品候選藥物是atacicept，這是一種每週自我注射一次的融合蛋白，作爲皮下注射使用，能夠阻斷b細胞激活因數(BAFF)和誘導增殖配體(APRIL)，這兩者刺激b細胞和漿細胞產生自體抗體，從而導致某些自身免疫疾病，包括IgAN，也稱爲Berger病，以及狼瘡性腎炎。此外，Vera還在評估atacicept可能在其他疾病中減少自體抗體的醫學用途。Vera還在開發MAU868，這是一種單克隆抗體，旨在中和BK病毒(BKV)感染，BK病毒是一種多瘤病毒，在某些情況下如腎移植中可能產生嚴重後果。Vera保留atacicept和MAU868的所有全球開發和商業權利。欲了解更多信息，請訪問。
For more information, please contact:
如需更多信息，請聯繫：
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
投資者聯繫人：
喬伊斯·阿拉爾
LifeSci顧問
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
媒體聯繫人：
梅德琳·霍廷
通信
MHawtin@lifescicomms.com
譯文內容由第三人軟體翻譯。